Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + nab-paclitaxel + apatinib first-line study in unresectable pancreatic cancer
ChiCTR2100045844Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, paclitaxel and Rivoceranib in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxelRivoceranib
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2100045844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045844.